Muutke küpsiste eelistusi

Neurobiology, Physiology, and Psychology of Pain [Pehme köide]

Edited by , Edited by (Consultant, Medical Protocol Department, King Abdulaziz Medical City, Ministry of National Guard Heath Affairs, Riyadh, Saudi Arabia), Edited by (Professor, Department of Clinical Biochemistry, Kings College Hospital, London, UK; Emeritus Profes), Edited by
  • Formaat: Paperback / softback, 458 pages, kõrgus x laius: 276x216 mm, kaal: 1230 g, Approx. 125 illustrations; Illustrations, Contains 1 Paperback / softback and 1 Digital (delivered electronically)
  • Ilmumisaeg: 16-Feb-2022
  • Kirjastus: Academic Press Inc
  • ISBN-10: 012820589X
  • ISBN-13: 9780128205891
Teised raamatud teemal:
  • Formaat: Paperback / softback, 458 pages, kõrgus x laius: 276x216 mm, kaal: 1230 g, Approx. 125 illustrations; Illustrations, Contains 1 Paperback / softback and 1 Digital (delivered electronically)
  • Ilmumisaeg: 16-Feb-2022
  • Kirjastus: Academic Press Inc
  • ISBN-10: 012820589X
  • ISBN-13: 9780128205891
Teised raamatud teemal:

The Neurobiology, Physiology and Psychology of Pain focuses on bettering readers’ understanding of acute and chronic pain. Featuring chapters on neurotransmitters, pharmacology, and brain imaging, this volume discusses, in detail, the mechanisms of pain and experimental studies undertaken to better understand the pathways involved. The translational work in this area has applicability for neurologists, anesthesiologists, pharmacologists, and anyone working in the intersection of these areas. This volume is integral for anyone interested in the molecular underpinnings of pain at every level.

Contributors xv
Preface xxi
Part I Molecular and cellular aspects
1 KCNQ/Kv7 channels as therapeutic target to treat neuropathic pain
Zizhen Wu
Qing Yang
Introduction
3(1)
KCNQ/Kv7 channel family members
3(1)
KCNQ proteins and function
3(1)
KCNQ channel compositions
4(1)
KCNQ channels in primary sensory neurons and their contribution to neuropathic pain
5(2)
Primary sensory neurons and neuropathic pain
5(1)
KCNQ channels in primary sensory neurons
6(1)
Plasticity of KCNQ channels and their contribution to neuropathic pain
6(1)
KCNQ channels as therapeutic target to treat neuropathic pain
7(1)
KCNQ channels as therapeutic target to treat established pain
7(1)
KCNQ channels as therapeutic target to prevent the development of neuropathic pain
8(1)
Challenges
8(1)
Applications to other areas
9(1)
Other agents of interest
10(1)
Mini-dictionary of terms
10(1)
Key facts of KCNQ/Kv7 channels and neuropathic pain
10(1)
Summary points
10(1)
References
10(3)
2 A new mutation in NTRK1 gene is associated with congenital insensitivity to pain without anhidrosis
Mogge Hajiesmaeil
Fatemeh Yazarlou
Maryam Sobhani
Soudeh Ghafouri-Fard
Introduction
13(6)
The applications to other areas
19(1)
Mini-dictionary of terms
19(1)
Key facts
20(1)
Summary points
20(1)
References
20(3)
3 Prdm12, a key transcriptional regulator of the nociceptive lineage
Simon Vermeiren
Simon Desiderio
Eric I. Bellefroid
Introduction
23(1)
Painlessness genes
24(1)
Mutations in PRDM12 cause CIP and midface toddler excoriation syndrome
25(1)
Prdm12 is selectively expressed in developing somatosensory ganglia in the nociceptive lineage
26(1)
Prdm12 is essential for the emergence of the entire nociceptive lineage
26(1)
How does Prdm12 function in the specification and maturation of nociceptive neurons?
26(1)
Does Prdm12 play a role in mature nociceptors?
27(1)
Applications to other areas
28(1)
Other agents of interest
28(1)
Mini-dictionary of terms
29(1)
Key facts showing the importance of Prdm12 in nociceptors
29(1)
Summary points
29(1)
References
29(4)
4 Genetics of chronic widespread musculoskeletal pain
Maria Jesus Alvarez-Cubero
Sergio Cuenca-Lopez
Veronica Arenas-Rodriguez
Fernando Estevez-Lopez
Luis Javier Martinez-Gonzalez
Introduction
33(1)
Heritability of chronic widespread musculoskeletal pain
34(1)
Candidate gene studies in chronic widespread musculoskeletal pain
34(5)
Case-control studies
35(3)
Association genotype-phenotype
38(1)
SNPs that has been studied in only one analysis in fibromyalgia
38(1)
GWAS
39(1)
Interactions (gene-gene and gene-environment)
39(1)
Future perspectives (mainly, research agenda)
40(1)
Applications to other areas
41(1)
Mini-dictionary of terms
41(1)
Key facts
41(1)
Summary points
41(1)
References
41(4)
5 Fentanyl: Polymorphisms, and adverse events
Mongi Benjeddou
Ana M. Peiro
Opioid fentanyl use in pain management
45(4)
Fentanyl pharmacology
46(1)
Fentanyl safety profile
47(1)
Fentanyl misuse and abuse
48(1)
Potential pharmacogenetics markers in fentanyl pain management
49(3)
Candidate genes
50(2)
Barriers to implementation
52(1)
Conclusions
53(1)
Applications to other areas
53(1)
Other agents of interest
53(1)
Mini-dictionary of terms
53(1)
Key facts of fentanyl
54(1)
Summary points
54(1)
References
54(3)
6 Propofol anesthesia and molecular changes in the brain
Desanka Milanovic
Zeljko Pavkovic
Vesna Pesic
Introduction
57(1)
Formulation matter
58(1)
Neural and molecular targets of propofol
58(3)
Propofol-induced brain molecular changes during postanesthesia period
59(1)
Molecular changes that reflect alterations in neuronal activity at the peak of brain growth spurt
59(1)
Age-dependent peculiarities in the expression of neurotrophins and their downstream signaling pathways
59(1)
Neuronal activity and synaptic plasticity
60(1)
Molecular autograph of longer exposures to propofol at the peak of the brain growth spurt
61(1)
Propofol and age-related brain pathology
61(1)
Applications to other areas
61(1)
Other agents of interest
62(1)
Mini-dictionary of terms
62(1)
Key fads of propofol anesthesia and molecular changes in the brain
63(1)
Summary points
64(1)
References
64(3)
7 Protein kinase G is a molecular switch for pain
Ying-Ju Sung
Richard T. Ambron
Introduction
67(1)
Pain is perceived via inputs from nociceptive circuits that are adaptive
67(2)
Nociception
67(1)
The acute perception of pain
68(1)
The prolonged perception of pain
68(1)
Long-term potentiation
68(1)
LTH and persistent pain
69(3)
Distinction between persistent and chronic pain
70(1)
LTH is induced by protein kinase G, a positive injury signal in nociceptive neurons
70(1)
PKG-1α is a nociceptive positive injury signal for LTH in rats
70(1)
Persistent activity of PKG-la in sensory neurons after nerve injury in rats
71(1)
Development of a novel potent PKG inhibitor
72(3)
N46 effectively alleviates chronic osteoarthritic and inflammation-induced pain
74(1)
Side effects and the fate of N46 in vivo
74(1)
Conclusions
75(1)
Applications to other areas
75(1)
Other agents of interest
75(1)
Mini-dictionary of terms
75(1)
Key facts
75(1)
Summary points
75(1)
References
76(3)
8 Adrenergic agonists and antagonists enhance opioid receptor activity
Robert Root-Bernstein
Introduction
79(1)
Anatomical and cellular codistribution of opioid and adrenergic functions
79(1)
Mechanisms of adrenergic receptor-opioid receptor cross-talk
80(1)
Opioids bind to adrenergic receptors
80(1)
Adrenergic compounds bind to opioid receptors
80(1)
Opioid receptor-adrenergic receptor heterodimerization
81(1)
A model of adrenoceptor-opioid receptor cross-talk
81(3)
Synergistic effects of adrenergic-opioid receptor cross-talk in the treatment of pain
84(1)
Prevention of desensitization and mutual resensitization of opioid and adrenergic receptor function by each other's ligands
84(1)
Applications to other areas: Local anesthetic enhancement and opioid sparing uses
85(1)
Other agents of interest: Ascorbic acid, tramadol and tapentadol, and ketamine
85(1)
Mini-dictionary of terms
86(1)
Key facts
86(1)
Summary points
86(1)
References
86(5)
9 Inflammatory and neuropathic pain impact on the opioid function in the mesocorticolimbic system
Yolanda Campos-Jurado
Javier Cuitavi
Natalia Landsberg
Jesus D. Lorente
Lucia Hipolito
Introduction
91(1)
A short introduction to the opioid receptors
92(1)
The endogenous opioid system: A key component of analgesia, reward, and aversion
92(1)
Chronic pain alters brain function and connectivity recruiting motivational and emotional regions
92(2)
PET imaging confirms pain-induced alterations of ORs in the MCLS during pain
94(1)
Preclinical studies show altered MOR density or function derived from the presence of pain
94(2)
Animal models of pain showed altered DA-related behaviors derived from the pharmacological activation of MORs
96(2)
Inflammatory pain promotes increased opioid self-administration
98(1)
Dynorfin/KOR system (Dyn/KOR) of the MCLS: A new key player in pain field
98(1)
Applications to other areas
98(2)
Mini-dictionary of terms
100(1)
Key facts of pain-induced changes in OR function
100(1)
Summary points
100(1)
References
100(4)
10 Clinacanthus nutans L., analgesia, and the 1-arginine/nitric oxide-mediated/cyclic-guanosine monophosphate-independent pathway
Zainul Amiruddin Zakaria
Introduction
104(1)
Herbal remedies for the treatment of pain
104(1)
Clinacanthus nutans L.
104(1)
Report on findings related to the antinociceptive activity of C. nutans
104(2)
Antinociceptive profile of MCNL and the possible mechanisms of antinociception
104(2)
Antinociceptive profile of PEP and the possible mechanisms of antinociception
106(1)
Phytoconstituents of MCNL and PEP
107(1)
Conclusion based on the reported antinociceptive activity of MCNL and PEP
107(1)
Involvement of peripheral and central antinociceptive mechanisms
108(1)
Involvement of various mechanisms of antinociception
109(1)
Role of general opioidergic system
109(1)
Involvement of specific opioidergic system subtypes
110(1)
Role of nonopioidergic systems
110(1)
Involvement of transient receptor potential vanilloid type 1 (TRPV1) receptors, glutamatergic system, protein kinase C (PKC)-mediated pathway, and bradykininergic system
110(1)
Involvement of α2-adrenergic, β-adrenergic, adenosinergic, dopaminergic, or muscarinic cholinergic receptor systems
110(1)
Involvement of various types of K+ channels
111(1)
Role of NO-mediated pathways
111(1)
Applications to other areas
111(1)
Other agents of interest
112(1)
Mini-dictionary of terms
112(1)
Key facts
113(1)
Key facts of analgesia
113(1)
Summary points
113(1)
References
113(4)
11 The orally bioavailable imidazodiazepine, KRM-II-81, is a novel potentiator of α2/3-containing GABAA receptors with analgesic efficacy
Rok Cerne
Jodi L. Smith
Janet L. Fisher
Lalit K. Golani
Daniel E. Knutson
James M. Cook
Jeffrey M. Witkin
Introduction
117(1)
GABA receptors
117(1)
GABAA receptor potentiating benzodiazepines and pain
118(1)
Alpha 2/3-containing GABAA receptors
118(2)
KRM-II-81
120(1)
KRM-II-81 and pain
120(2)
Side effect burden
122(1)
Applications to other therapeutic areas
123(1)
Other agents of interest
123(1)
Mini-dictionary of terms
124(1)
Key facts
124(1)
Summary points
124(1)
Acknowledgments
124(1)
Conflict of interest
124(1)
References
124(3)
Further reading
127(2)
12 Extrasynaptic α5GABAA receptors and their role in nociception and pathological pain
Urzula Franco-Enzastiga
Yarim E. De la Luz-Cuellar
Luis Eduardo Hernandez-Reyes
Guadalupe Raya-Tafolla
Jorge E. Torres-Lopez
Janet Murbartian
Vinicio Granados-Soto
Rodolfo Delgado-Lezama
Introduction
129(1)
GABAA receptors
130(1)
Expression of α5GABAA receptors at spinal cord and DRG
130(1)
GABAergic tonic current in the spinal cord
130(2)
GABAergic tonic current in spinal cord in mammals
132(1)
Extrasynaptic α5GABAA receptors in the rate-dependent depression (RDD) of the Hoffmann reflex (HR)
132(1)
Function of extrasynaptic α5GABAA receptors in primary afferent fibers
133(1)
Extrasynaptic spinal a5GABAA receptors in pain
133(1)
Extrasynaptic α5GABAA receptors regulation
133(1)
Applications to other areas
133(2)
Other agents of interest
135(1)
Mini-dictionary of terms
135(1)
Key facts on α5GABAA receptors in pain
135(1)
Summary points
135(1)
Acknowledgments
136(1)
References
136(3)
13 ATP-sensitive potassium channels in pain and analgesia
Tais de Campos Lima
Debora de Oliveira Santos
Celina Monteiro da Cruz Lotufo
ATP-sensitive potassium channels (Katp)
139(2)
Possible role for Katp channels in primary nociceptive neurons during hyperglycemia
141(2)
Katp involvement in the mechanisms of analgesic substances
143(3)
Application to other areas
146(1)
Other agents of interest
146(1)
Mini-dictionary of terms
146(1)
Key facts
146(1)
Summary points
147(1)
References
147(4)
14 Astrocyte-neuron lactate shuttle and pain
Keisuke Miyamoto
Masahiro Ohsawa
Introduction
151(3)
Applications to other areas
154(1)
Other agents of interest
154(2)
Mini-dictionary of terms
156(1)
Key facts
157(1)
Key facts of astrocyte-neuron lactate shuttle
157(1)
Summary points
157(1)
References
157(4)
15 Nociception and sweet solutions: Applications to inflammatory pain
Khawla Q. Nuseir
Manal Kassab
Ahmad Altarifi
Introduction
161(1)
Inflammatory pain pathways
162(1)
Pain behaviors and assessment
163(1)
Use of sweet solutions for inflammatory pain
163(1)
Mechanisms of sweet solutions for inflammatory pain
164(1)
Sweet tasting solutions used for analgesia
164(1)
Clinical applications
164(1)
Importance of treatment of neonatal pain
165(1)
Applications to other areas
165(1)
Other agents of interest
165(1)
Other agents of interest
166(1)
Mini-dictionary of terms
166(1)
Key facts
166(1)
Key facts of prematurity
166(1)
Summary points
166(1)
References
167(5)
16 Interlinking interleukin-33 (IL-33), neuroinflammation and neuropathic pain
Camila Rodrigues Ferraz
Fernanda Soares Rasquel-Oliveira
Sergio Marques Borghi
Anelise Franciosi
Thacyana Teixeira Carvalho
Telma Saraiva-Santos
Nayara Anitelli Artero
Rubia Casagrande
Waldiceu A. Verri Jr
IL-33
172(1)
Neuropathic pain and glial cells
173(1)
IL-33 and glial cells
174(2)
Oligodendrocytes
174(1)
Microglia
175(1)
Astrocytes
176(1)
Applications to other areas
176(1)
Other agents of interest
177(1)
Mini-dictionary of terms
177(1)
Key facts of IL-33 in neuropathic pain
177(1)
Summary points
178(1)
Funding
178(1)
References
179(5)
17 Neurons of the parabrachial nucleus, nociceptive input, and pain pathways
Yosuke Arima
Yoshinori Otani
Masashi Fujitani
Introduction
184(1)
Anatomy of the PBN
185(1)
Afferent pain transmitting pathways to the LPB
186(1)
Nociceptive neurons in the LPB and their aversive pathway to amygdala and bed nucleus of the stria terminalis (BNST)
186(1)
CGRP-positive neurons in the PBeI
187(1)
Nociceptive neurons in the LPB and their autonomic connection with the hypothalamus
187(1)
Pain-modulating pathways from the LPB
187(1)
Conclusion
188(1)
Applications to other areas
188(1)
Mini-dictionary of terms
189(1)
Summary points
189(1)
References
189(4)
18 Anterior cingulate cortex, pain perception, and pathological neuronal plasticity during chronic pain
Fernando Kasanetz
Mario A. Acuna
Thomas Nevian
Introduction
193(1)
ACC is a critical hub linking neuronal circuits for nociception and emotion
194(1)
ACC activation is associated with the affective component of pain
194(1)
ACC neuronal activity mediates pain-induced negative affect
195(1)
Nociception-related neurons in the ACC
196(1)
Distinct cortical representation of acute and chronic pain
197(1)
Pathological neuronal plasticity in the ACC associated to chronic pain
198(1)
Applications to other areas
198(1)
Interfering with pathological cortical plasticity as a therapeutic approach for chronic pain
198(1)
Other agents of interest
199(1)
Anterior insular cortex and pain affect
199(1)
Mini-dictionary of terms
200(1)
Key facts
200(1)
Key facts of neuronal plasticity in health and disease
200(1)
Summary points
200(1)
References
201(2)
19 Sleep deprivation, headache, and Fos immunohistochemistry
Seonghoon Kim
Jeong-wook Park
Introduction
203(1)
Pain, headache, and sleep deprivation
203(1)
The pathophysiologic relationship between sleep deprivation and headache
204(1)
Modulation of headache and sleep-wake cycles
204(1)
Headache
204(1)
Sleep
205(1)
Pharmacologic relationships between headache and sleep
205(2)
Adenosine
205(1)
Orexin
206(1)
Melatonin
207(1)
Pituitary adenylate cyclase activating peptide (PACAP)
207(1)
Experimental research to examine headache and sleep deprivation
207(4)
Fos-immunohistochemistry
207(1)
Animal model of sleep deprivation
208(2)
Animal model of headache (activation of the trigeminovascular system)
210(1)
Experimental studies of sleep deprivation and headache pain
211(2)
Applications to other areas
213(1)
Mini-dictionary of terms
213(1)
Key facts
213(1)
Key facts of sleep deprivation and headache
213(1)
Summary points
213(1)
References
213(5)
20 Antinociceptive glucagon-like peptides
Duygun Albrita Aykan
Introduction to the glucagon-like peptides
218(1)
Applications to other areas
218(1)
Glucagon-like peptide-1 and its analogs
219(2)
Glucagon-like peptide-2
221(1)
Other agents of interest
222(1)
Mini-dictionary of terms
223(1)
Key facts of glucagon-like peptides
223(1)
Summary points
223(1)
References
223(5)
21 Pain transmission and peripheral group III metabotropic glutamate receptors (mGluRs)
Eui Ho Park
Hee Chul Han
Introduction
228(1)
Glutamate metabolism in peripheral nervous system
228(1)
Glutamate release and pain
228(1)
Glutamate receptor signaling: iGluR and mGluR
229(1)
Localization of peripheral group III mGluR
229(1)
Negative modulation of pain transmission
230(3)
Group III mGluRs in non-neuronal glial cells
233(1)
Applications to other areas
234(1)
Other agents of interest
235(1)
Mini-dictionary of terms
235(1)
Key facts of activity-dependent inhibition
235(1)
Summary points
235(1)
References
236(3)
22 TRPM8 receptor and menthol in pain management
Hannu Kokki
Merja Kokki
Introduction
239(1)
Transient receptor potential channels
240(1)
Menthol
240(1)
Multimodal pain therapy
241(3)
Posttraumatic and postoperative pain
244(1)
Musculoskeletal pain
244(1)
Neuropathic pain
245(1)
Headache and migraine
246(1)
Pregnant and lactating women
246(1)
Children and adolescent
247(1)
Elderly
247(1)
Obesity
247(1)
Other agents of interest
247(1)
Applications to other areas
248(1)
Mini-dictionary of terms
248(1)
Key facts of TRPM8 receptor and menthol
249(1)
Summary points
249(1)
References
249(2)
Further reading
251(4)
Part II Physiology, imaging and physical recordings
23 Anesthetic and proconvulsant effects of ketamine on EEG
Shaila Gowda
Charles Akos Szabo
Introduction
255(1)
Ketamine effects as anesthetic
256(1)
Ketamine effects as proconvulsant
257(1)
EEG analysis of ketamine effects
257(1)
Scalp vs intracranial EEG effects of ketamine in nonhuman primate model of an idiopathic generalized epilepsy
258(1)
Effects of other agents on EEG
259(2)
Key facts of anesthetic and proconvulsant effects of ketamine on EEG
261(1)
Summary points
261(1)
References
261(4)
24 Electroencephalography and anesthetic doses of ketamine
Logan Voss
Jamie Sleigh
Introduction
265(1)
Spectral EEG changes
265(5)
Connectivity metrics
267(1)
Neurophysiological underpinnings of the EEG effects of ketamine
268(1)
Interactions between ketamine and other hypnotic drugs
269(1)
Applications to other areas
270(1)
Other agents of interest
270(1)
Mini dictionary of terms
271(1)
Key facts
271(1)
Summary points
271(1)
References
272(3)
25 Linking heart function and analgesia
Giorgia Saltelli
Antonella Paladini
Martina Rekatsina
Giustino Varrassi
Introduction
275(1)
Analgesic drugs
276(6)
Opioids
276(1)
NSAIDs
277(5)
Paracetamol
282(1)
Application to other areas: Effects of NSAIDs on the kidney
282(1)
Other agents of interest: Adjuvants
282(1)
Mini-dictionary of terms
283(1)
Summary points
284(1)
References
284(3)
26 Computed tomography-guided procedures for epidural injections
Rohit Aiyer
Semih Gungor
Introduction
287(1)
General principles and technique common to all types of CT-guided epidural injections
287(2)
Patient positioning
287(1)
Three phases of CT-guided interventions
287(2)
Epidural injections
289(5)
Interlaminar epidural injections
290(1)
Cervical transforaminal epidural steroid injections
290(1)
Thoracic transforaminal epidural steroid injections
291(1)
Lumbar transforaminal steroid injections
292(2)
Radiation safety
294(1)
Complications
294(1)
Conclusion
295(1)
Applications to other areas
295(1)
Other agents of interest
295(1)
Mini-dictionary of terms
296(1)
Key facts
296(1)
Summary points
296(1)
References
296(3)
27 Chronic pain: Linking deep brain stimulation and sensory functional MRI
Witold H. Polanski
Johann Klein
Introduction
299(1)
History of deep brain stimulation for chronic pain
299(1)
Central pain processing
300(1)
Modern visualization of DBS targets
301(1)
Application to other areas
302(1)
Other methods of interest
302(1)
Mini-dictionary of terms
303(1)
Key facts
303(1)
Key facts of deep brain stimulation
303(1)
Key facts of sensory functional MRI
303(1)
Key facts of diffusion tensor imaging (DTI)
304(1)
Summary points
304(1)
References
304(3)
28 Neurocognition and placebo analgesia: Linking in functional magnetic resonance imaging
Sara Palermo
Introduction
307(1)
Understanding the placebo effect: From the biological approach to the advent of neuroimaging techniques
308(1)
Pain modulatory mechanisms relevant for the neuroimaging study of PA
309(1)
Pain and nociceptive stimuli in neuroimaging study of PA
309(1)
Pain evaluation and temporal phases in neuroimaging study of PA
310(1)
Sample characteristic relevant for the neuroimaging study of PA
310(1)
Neurocognitive predictors in neuroimaging study of PA: Attention, expectation, and reappraisal
311(1)
The neuroimaging meta-analytic approach to the study of PA and related neurocognitive factors
312(1)
Neuroimaging findings in the study of PA in Alzheimer's disease
313(1)
Future directions
313(1)
Applications to other areas
313(1)
Other agents of interest
314(1)
Mini-dictionary of terms
314(1)
Key facts of functional magnetic resonance imaging
314(1)
Summary points
315(1)
References
315(5)
29 Linking the cortex, functional spectroscopy, and pain: Features and applications
Wolnei Caumo
Janete S. Bandeira
Jairo Alberto Dussan-Sarria
Basic concepts
320(1)
Cortical functions related to pain processing
320(1)
Role of the motor cortex in pain processing
321(1)
Role of the PFC in pain processing
322(1)
Nature of brain region's recruited during pain: Insights from human imaging studies
322(1)
The biological rationale behind near-infrared spectroscopy
322(1)
fNIRS neuroimaging: Technical aspects, advantages, limitations, and applications
323(3)
The sequence of steps to perform neuroscience studies using fNIRS
326(1)
Dynamic trace pattern evoked by electrical stimulation
327(1)
Applications of fNIRS in pain research
327(3)
fNIRS and cortical connectivity in pain research
330(1)
Remarks and future directions
331(1)
Applications to other areas
331(1)
Mini-dictionary of terms
332(1)
Key factors related to fNIRS
332(1)
Summary points
332(1)
References
333(4)
30 Muscle origins of myofascial pain syndrome
Eva Maria Martinez-Jimenez
Daniel Lopez-Lopez
Carlos Romero-Morales
Victoria Mazoteras-Pardo
Marta Elena Losa-Iglesias
David Rodriguez-Sanz
Marta San-Antolin-Gil
Ricardo Becerro-de-Bengoa-Vallejo
Cesar Calvo-Lobo
Introduction
337(1)
Nociception in muscle tissue
338(1)
Referred pain and peripheral sensitization process
339(1)
Sympathetic facilitation of muscle pain
339(1)
Central sensitization
339(3)
Clinical applications
342(1)
Conclusion
342(1)
Application to other areas
342(1)
Other agents of interest
342(1)
Mini-dictionary of terms
342(1)
Key facts of myofascial pain
343(1)
Summary points
343(1)
References
343(6)
Part III Psychology and behavior
31 Behavioral markers of pain: Understanding the cognitive, motor, and societal interactions in the pain experience
S.A. Holmes
A. Quinlan
M.E. Pierce
Psychology and cognition
349(2)
Fear avoidance
349(1)
Pain catastrophizing
349(1)
Cognitive performance
350(1)
Comorbidities and chronic pain
350(1)
Motor behavior
351(1)
Motor response to pain
351(1)
Changing our motor behaviors
351(1)
Social interactions and pain behavior convention
352(2)
Social interaction
352(1)
Community structure-Access to resources
353(1)
Biological sex and gender
353(1)
What is coming in the next 5-10 years?
354(1)
Conclusion
354(1)
Application to other areas
355(1)
Other agents of interest
355(1)
Mini-dictionary of terms
355(1)
Key facts
355(1)
Summary points
356(1)
References
356(3)
32 Adverse life events, sensitization of spinal nociception, and chronic pain risk
Jamie L. Rhudy
Natalie Hellman
Adverse life events: A definition
359(1)
Adverse life events and health
359(1)
Adverse life events and chronic pain
359(1)
The impact of adversity (stress) on nociception in animals
360(1)
Pain systems and their assessment in humans
360(1)
Adversity and pain processing in humans
361(7)
Adversity, latent sensitization, and pain risk
368(1)
Implications and future directions
369(1)
Summary
370(1)
Applications to other areas
371(1)
Other agents of interest
371(1)
Mini-dictionary of terms
371(1)
Key facts about adversity
371(1)
Summary points
371(1)
Conflict of interest
372(1)
References
372(3)
33 Cognitive-affective modulation of pain: The placebo and nocebo phenomena and their impact on pain treatment
Sergiu Albu
Hans Linsenbardt
Mary W. Meagher
Introduction
375(1)
Psychological mechanisms of placebo analgesia and nocebo hyperalgesia
376(1)
Neurobiological and neurochemical mechanisms of placebo analgesia and nocebo hyperalgesia
377(3)
The relevance of placebo and nocebo effects for pain treatment in clinical practice
380(2)
Applications to other areas
382(1)
Placebo and nocebo phenomena related to nonopioid drugs and implications for pain treatment
382(1)
Other agents of interest
382(1)
Role of cognitive behavioral therapy in placebo/nocebo and pain treatment
382(1)
Mini-dictionary of terms
383(1)
Key facts of placebo analgesia
383(1)
Key facts of nocebo hyperalgesia
384(1)
Summary points
384(1)
References
385(2)
34 Nociception-related behavioral phenotypes in adult zebrafish
Fabiano V. Costa
Luiz V. Rosa
Allan V. Kalueff
Denis B. Rosemberg
Introduction
387(1)
Nociception and pain in animal models
387(1)
Zebrafish as animal model for translational pain research
388(1)
Zebrafish-based pain models
389(1)
Applications to other areas
390(1)
Other agents of interest
390(1)
Mini-dictionary of terms
391(1)
Key facts
391(1)
Key facts of zebrafish
391(1)
Summary points
391(1)
References
391(4)
35 Pain, implantable pain devices, and psychosocial aspects of pain
Vishal Varshney
Thomas Rutledge
Maya D'Eon
Krishnan Chakravarthy
Anatomy of pain pathways
395(1)
Psychosocial aspects of neuropathic pain
396(1)
Rationale for psychosocial evaluations
397(1)
Effect of spinal cord stimulation on pain processing
398(1)
Effects of modes of stimulation on psychosocial aspects of pain
399(1)
Conclusions
400(1)
Application to other areas
401(1)
Other agents of interest
401(1)
Mini-dictionary of terms
401(1)
Key facts of pain, implantable devices, and psychosocial aspects of pain
401(1)
Summary points
402(1)
References
402(3)
36 Influence of psychological factors on myofascial pain
Marta San-Antolin-Gil
Daniel Lopez-Lopez
Ricardo Becerro-de-Bengoa-Vallejo
Marta Elena Losa-Iglesias
Carlos Romero-Morales
David Rodriguez-Sanz
Victoria Mazoteras-Pardo
Eva Maria Martinez-Jimenez
Cesar Calvo-Lobo
Introduction
405(7)
Myofascial trigger point types
405(1)
Relationship between psychological factors and myofascial pain
406(1)
Personality traits and myofascial pain
406(2)
Anxiety and myofascial pain
408(1)
Depression and myofascial pain
409(1)
Catastrophism and myofascial pain
409(1)
Pain fear-avoidance and kinesiophobia and myofascial pain
410(1)
Central sensitization and myofascial pain
411(1)
Clinical applications
411(1)
Application to other areas
412(1)
Other agents of interest
412(1)
Mini-dictionary of terms
412(1)
Key facts of myofascial pain
412(1)
Summary points
412(1)
References
412(7)
Part IV Resources
37 Recommended resources, sites, and research groups for the neuroscience of anesthetics and analgesics
Rajkumar Rajendram
Vinood B. Patel
Victor R. Preedy
Introduction
419(1)
Resources
420(1)
Applications to other areas
420(4)
Mini-dictionary of terms
424(1)
Key points
425(1)
Summary points
425(1)
Acknowledgments
425(1)
References
426(1)
Index 427
Dr Rajkumar Rajendram is a clinician scientist with a focus on internal medicine, anaesthesia, intensive care and peri-operative medicine. He graduated with distinctions from Guys, Kings and St. Thomas Medical School, Kings College London in 2001. As an undergraduate he was awarded several prizes, merits and distinctions in pre-clinical and clinical subjects.

Dr Rajendram began his post-graduate medical training in general medicine and intensive care in Oxford. He attained membership of the Royal College of Physicians (MRCP) in 2004 and completed specialist training in acute and general medicine in Oxford in 2010. Dr Rajendram subsequently practiced as a Consultant in Acute General Medicine at the John Radcliffe Hospital, Oxford.



Dr Rajendram also trained in anaesthesia and intensive care in London and was awarded a fellowship of the Royal College of Anaesthetists (FRCA) in 2009. He completed advanced training in regional anaesthesia and intensive care. He was awarded a fellowship of the Faculty of Intensive Care Medicine (FFICM) in 2013 and obtained the European diploma of intensive care medicine (EDIC) in 2014. He then moved to the Royal Free London Hospitals as a Consultant in Intensive Care, Anaesthesia and Peri-operative Medicine. He has been a fellow of the Royal College of Physicians of Edinburgh (FRCP Edin) and the Royal College of Physicians of London (FRCP Lond) since 2017 and 2019 respectively. He is currently a Consultant in Internal Medicine at King Abdulaziz Medical City, National Guard Heath Affairs, Riyadh, Saudi Arabia.

Dr Rajendrams focus on improving outcomes from Coronavirus Disease 2019 (COVID-19) has involved research on point of care ultrasound and phenotypes of COVID-19. Dr Rajendram also recognises that nutritional support is a fundamental aspect of medical care. This is particularly important for patients with COVID-19. As a clinician scientist he has therefore devoted significant time and effort into nutritional science research and education. He is an affiliated member of the Nutritional Sciences Research Division of Kings College London and has published over 400 textbook chapters, review articles, peer-reviewed papers and abstracts.

Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at Kings College Hospital and Emeritus Professor of Nutritional Biochemistry at Kings College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at Kings College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books. Vinood B. Patel, BSc, PhD, FRSC, is currently Professor in Clinical Biochemistry at the University of Westminster. In 2014 Dr Patel was elected as a Fellow to The Royal Society of Chemistry. Dr Patel graduated from the University of Portsmouth with a degree in Pharmacology and completed his PhD in protein metabolism from Kings College London in 1997. His postdoctoral work was carried out at Wake Forest University Baptist Medical School, NC, USA studying structural-functional alterations to mitochondrial ribosomes, where he developed novel techniques to characterize their biophysical properties. Research is being undertaken to study the role of nutrients, antioxidants, phytochemicals, iron, alcohol and fatty acids in the pathophysiology of liver disease. Other areas of interest are identifying new biomarkers that can be used for the diagnosis and prognosis of disease and understanding mitochondrial oxidative stress in neurological disorders and iron dysregulation in diabetes. Dr Patel is a nationally and internationally recognized researcher and has several edited biomedical books related to the use or investigation of active agents or components. These books include The Handbook of Nutrition, Diet, and Epigenetics, Branched Chain Amino Acids in Clinical Nutrition, Cancer: Oxidative Stress and Dietary Antioxidants, Toxicology: Oxidative Stress and Dietary Antioxidants, Molecular Nutrition: Vitamins, The Neuroscience of Pain, Cognitive Behavioural Therapy. He is Editor of the ten-volume series Biomarkers in Disease: Methods, Discoveries and Applications. Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries.